螺杂环单羰基姜黄素类似物的合成、晶体结构与抗肿瘤活性研究

doi:10.6023/cjoc201402004

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (699 KB) HTML (0 KB)
输出: BibTeX | EndNote (RIS)

摘要为了发现新型姜黄素类抗肿瘤先导化合物，通过1，3-偶极环加成反应合成了14个螺杂环单羰基姜黄素类似物. 该反应利用无需加催化剂的“一锅煮”方法合成，具有环境友好的优点. 所有化合物结构经ESI-MS、ESI-HRMS和¹H NMR确认，通过X衍射确证B6的晶体结构为单斜晶系，该类化合物的合成具有良好的区域选择性和立体选择性. 通过噻唑兰（MTT）法测定所有化合物对人胃癌细胞SGC-7901、神经胶质瘤细胞U251、人大细胞肺癌细胞株NCI-H460的增殖抑制活性，部分化合物表现出了较好的活性. 其中B1、B6、B7和B11对三种肿瘤细胞均表现出较好的抗肿瘤活性，而对正常人肝细胞HL-7702显示了相对较低的细胞毒性. 化合物B1和B7均能明显诱导凋亡相关蛋白含半胱氨酸的天冬氨酸蛋白水解酶3（caspase3）和多聚ADP-核糖聚合酶（PARP）的活化，诱导肿瘤细胞发生凋亡. 所合成的螺杂环单羰基姜黄素类似物为新型的抗肿瘤化合物，该类化合物可能在靶向抗肿瘤药物研发方面具有较好的研究前景.

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴建章
	翁碧霞
	仇佩虹
	蔡志坚
	范蕾
	应士龙
	张秀华
	吴晓萍
	梁广

关键词 ：单羰基姜黄素类似物, 螺杂环, 抗肿瘤, 合成

Abstract：To discover novel lead compounds with good antitumor activity and low toxicity, 14 spiroheterocycle mono-car- bonyl analogs of curcumin (MCACs) were synthesized by 1,3-dipolar cycloaddition reaction. The one-pot reaction was carried out without catalyst, which showed the advantage of environmentally friendly. The structures of all compounds were characterized by ESI-MS, ESI-HRMS and ¹H NMR. The crystal structure of B6 was confirmed as monoclinic system by X-ray diffraction, which indicated high region-selectivity and stereo-selectivity in the reaction of these compounds. All compounds were screened for their abilities to inhibit the growth of human gastric cell SGC-7901, glioma cell U251, human large cell lung cancer cell lines NCI-H460 by thiazolyl blue tetrazolium bromide (MTT) assay, and some of them showed good antitumor activity. Among the active compounds, B1, B6, B7 and B11 exhibited strong antitumor efficacy on the three tumor cells and low cytotoxicity against human liver cells HL-7702. Both compounds B1 and B7 can significantly induce the activation of apoptosis related proteins cysteinyl aspartate specific proteinase (caspase3) and poly ADP-ribose polymerase (PARP), and induce the apoptosis of tumor cell. The synthesized spiro heterocycles derived from MCACs in this study were novel antitumor compounds, and these compounds appeared to possess good research prospect in the area of anti-tumor drugs.

Key words： mono-carbonyl analogs of curcumin spiro-heterocyclic antitumor synthesis

收稿日期: 2014-02-05 出版日期: 2014-05-05

基金资助:国家自然科学基金（Nos.81272462，81102310）、浙江省自然科学基金（Nos.LY12H30004，Y4090379）、浙江省医药卫生科技计划（No.2012KYA129）、温州市科技局（No.S20100045）、浙江省重点科技创新团队（Nos.2010R50042-04）资助项目

通讯作者: 张秀华，吴晓萍 E-mail: wjzwzmc@126.com,wujianzhang6@163.com

引用本文:

吴建章, 翁碧霞, 仇佩虹, 蔡志坚, 范蕾, 应士龙, 张秀华, 吴晓萍, 梁广. 螺杂环单羰基姜黄素类似物的合成、晶体结构与抗肿瘤活性研究[J]. 有机化学, 2014, 34(8): 1573-1581. Wu Jianzhang, Weng Bixia, Qiu Peihong, Cai Zhijian, Fan Lei, Ying Shilong, Zhang Xiuhua, Wu Xiaoping, Liang Guang. Synthesis, Crystal Structure, Antitumor Activity of Spiro-heterocyclic Mono-carbonyl Analogues of Curcumin. Chin. J. Org. Chem., 2014, 34(8): 1573-1581.

链接本文:

http://sioc-journal.cn/Jwk_yjhx/CN/10.6023/cjoc201402004 或 http://sioc-journal.cn/Jwk_yjhx/CN/Y2014/V34/I8/1573

[1] Bar-Sela, G.; Epelbaum, R.; Schaffer, M. Curr. Med. Chem. 2010, 17, 190.
[2] Zhao, C.; Liu, Z.; Liang, G. Curr. Pharm. Design 2013, 19, 2114.
[3] Agrawal, D. K.; Mishra, P. K. Med. Res. Rev. 2010, 30, 818.
[4] Wu, J.; Wang, C.; Cai, Y.; Yang, S.; Zheng, X.; Qiu, P.; Peng, J.; Wu, X.; Liang, G.; Li, X. Chin. J. Org. Chem. 2010, 30, 884 (in Chinese).
(吴建章, 王聪, 蔡跃飘, 杨树林, 郑晓咏, 仇佩虹, 彭景, 吴晓萍, 梁广, 李校堃, 有机化学, 2010, 30, 884.)
[5] Wu, J.; Li, J.; Cai, Y.; Pan, Y.; Ye, F.; Zhang, Y.; Zhao, Y.; Yang, S.; Li, X.; Liang, G. J. Med. Chem. 2011, 54, 8110.
[6] Wang, Y.; Xiao, J.; Zhou, H.; Yang, S.; Wu, X.; Jiang, C.; Zhao, Y.; Liang, D.; Li, X.; Liang, G. J. Med. Chem. 2011, 54, 3768.
[7] Xiao, J.; Wang, Y.; Peng, J.; Guo, L.; Hu, J.; Cao, M.; Zhang, X.; Zhang, H.; Wang, Z.; Li, X.; Yang, S.; Yang, H.; Liang, G. Int. J. Cancer 2012, 131, 1455.
[8] Selvendiran, K.; Tong, L.; Vishwanath, S.; Bratasz, A.; Trigg, N. J.; Kutala, V. K.; Hideg, K.; Kuppusamy, P. J. Biol. Chem. 2007, 282, 28609.
[9] Wilken, R.; Veena, M. S.; Wang, M. B.; Srivatsan, E. S. Mol. Cancer 2011, 10, 12.
[10] Subramaniam, D.; May, R.; Sureban, S. M.; Lee, K. B.; George, R.; Kuppusamy, P.; Ramanujam, R. P.; Hideg, K.; Dieckgraefe, B. K.; Houchen, C. W.; Anant, S. Cancer Res. 2008, 68, 1962.
[11] Brown, A.; Shi, Q.; Moore, T. W.; Yoon, Y.; Prussia, A.; Maddox, C.; Liotta, D. C.; Shim, H.; Snyder, J. P. J. Med. Chem. 2013, 56, 3456.
[12] Zhang, J.; Yang, P. L.; Gray, N. S. Nat. Rev. Cancer 2009, 9, 28.
[13] Liang, G.; Liu, Z.; Wu, J.; Cai, Y.; Li, X. Trends Pharmacol. Sci. 2012, 33, 531.
[14] Dandia, A.; Jain, A. K.; Laxkar, A. K. RSC Adv. 2013, 3, 8423.
[15] George, R. F.; Ismail, N. S.; Stawinski, J.; Girgis, A. S. Eur. J. Med. Chem. 2013, 68, 341.
[16] Maheswari, S. U.; Balamurugan, K.; Perumal, S.; Yogeeswari, P.; Sriram, D. Bioorg. Med. Chem. Lett. 2010, 20, 7278.
[17] Wu, J.; Li, W.; Chen, L.; Chu, S.; Zhao, C. Chin. J. Org. Chem. 2012, 32, 2141 (in Chinese).
(吴建章, 李物兰, 陈玲姿, 楚生辉, 赵承光, 卫涛, 杨树林, 李校堃, 有机化学, 2012, 32, 2141.)
[18] Liang, G.; Yang, S. L.; Shao, L. L.; Zhao, C. G.; Xiao, J.; Lv, Y. X.; Yang, J.; Zhao, Y.; Li, X. K. J. Asian. Nat. Prod. Res. 2008, 10, 957.
[19] Liang, G.; Yang, S.; Zhou, H.; Shao, L.; Huang, K.; Xiao, J.; Huang, Z.; Li, X. Eur. J. Med. Chem. 2009, 44, 915.
[20] Katritzky, A. R.; Girgis, A. S.; Slavov, S.; Tala, S. R.; Stoyanova-Slavova, I. Eur. J. Med. Chem. 2010, 45, 5185.
[21] Wu, J.; Zhang, Y.; Cai, Y.; Wang, J.; Weng, B.; Tang, Q.; Chen, X.; Pan, Z.; Liang, G.; Yang, S. Bioorg. Med. Chem. 2013, 21, 3058.